A study of motivations and expectations of patients seen in phase 1 oncology clinics

Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, Sarah Stimpson, Janet Hanwell, Sonia Serrano Fandos, Sarah Stapleton, Thushara Ansari, Clare Peckitt, Stan Kaye, Juanita Lopez, Timothy A Yap, Winette van der Graaf, Johann de Bono, Udai Banerji, Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, Sarah Stimpson, Janet Hanwell, Sonia Serrano Fandos, Sarah Stapleton, Thushara Ansari, Clare Peckitt, Stan Kaye, Juanita Lopez, Timothy A Yap, Winette van der Graaf, Johann de Bono, Udai Banerji

Abstract

Background: To better inform clinical practice, this study was aimed at capturing patients' motivations for enrolling in phase 1 trials and at quantifying their expectations of the benefits, risks, and commitment associated with clinical trials and the impact of the initial consultation on their expectations.

Methods: This was a single-center, prospective, quantitative study of newly referred adult patients considering their first phase 1 oncology trial. Participants completed questionnaires before they were seen and an abbreviated follow-up version after their consultation.

Results: Questionnaires were completed by 396 (99%) and 301 (76%) before and after the clinic, respectively. Participants ranked the possibility of tumor shrinkage (84%) as the most important motivation for considering a phase 1 trial; this was followed by no alternative treatments (56%), their physician's recommendation (44%), and the fact that the research might benefit others (38%). When they were asked about the potential personal benefit, 43% predicted tumor shrinkage initially. After the consultation, this increased to 47%. Fourteen percent of patients expected a cure. When asked about risks, 71% of the participants expected moderate side effects. When asked about expectations of time commitments, a majority of patients did not anticipate weekly visits, although this was understood by 93% of patients after the consultation. Overall, patients were keen to consider trials and when asked before and after the consultation 72% and 84% were willing to enroll in studies, respectively.

Conclusions: This study reports that more than 80% of patients enroll in early-phase clinical oncology trials motivated by the potential of a clinical benefit, with approximately half expecting tumor shrinkage and approximately a tenth anticipating a cure. The typical phase 1 response rate is 4% to 20%, and this discrepancy exemplifies the challenges faced by patients and healthcare professionals during their interactions for phase 1 studies. Cancer 2016;122:3501-3508. © 2016 American Cancer Society.

Keywords: cancer; oncology clinical trials; patient expectations; patient motivations; phase 1 trials.

© 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

References

    1. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895–904.
    1. Roberts TG Jr, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292:2130–2140.
    1. Postel‐Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in phase‐I trials of novel molecularly targeted agents: does dose matter? Br J Cancer. 2009;100:1373–1378.
    1. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008;98:1029–1033.
    1. Weinfurt KP. Outcomes research related to patient decision making in oncology. Clin Ther. 2003;25:671–683.
    1. Wright JR, Whelan TJ, Schiff S, et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol. 2004;22:4312–4318.
    1. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care. 2003;12:114–122.
    1. Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients' decision‐making process regarding participation in phase I oncology research. J Clin Oncol. 2006;24:4479–4484.
    1. Brown R, Bylund CL, Siminoff LA, Slovin SF. Seeking informed consent to phase I cancer clinical trials: identifying oncologists' communication strategies. Psychooncology. 2011;20:361–368.
    1. Fallowfield LJ, Solis‐Trapala I, Jenkins VA. Evaluation of an educational program to improve communication with patients about early‐phase trial participation. Oncologist. 2012;17:377–383.
    1. Jenkins V, Solis‐Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ. What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol. 2011;29:61–68.
    1. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician‐patient communication. J Clin Oncol. 2003;21:2589–2596.
    1. Daugherty CK, Banik DM, Janish L, Ratain MJ. Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000;22:6–14.
    1. Sulmasy DP, Astrow AB, He MK, et al. The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer. 2010;116:3702–3711.
    1. Kass N, Taylor H, Fogarty L, et al. Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics. 2008;3:57–68.
    1. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol. 2000;18:421–428.
    1. Kass NE, Sugarman J, Medley AM, et al. An intervention to improve cancer patients' understanding of early‐phase clinical trials. IRB. 2009;31:1–10.
    1. Weinfurt KP, Seils DM, Lin L, et al. Research participants' high expectations of benefit in early‐phase oncology trials: are we asking the right question? J Clin Oncol. 2012;30:4396–4400.
    1. Moore S. A need to try everything: patient participation in phase I trials. J Adv Nurs. 2001;33:738–747.
    1. Karavasilis V, Digue L, Arkenau T, et al. Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur J Cancer. 2008;44:978–982.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner